The EMA’s CHMP has endorsed Ondibta for diabetes and Osqay for osteoporosis, a move that could broaden access to effective, lower-cost biologics across the European Union.
Medscape News Europe
Source link : https://www.medscape.com/viewarticle/eu-clears-path-biosimilars-diabetes-bone-health-2025a1000vxz?src=rss
Author :
Publish date : 2025-11-17 15:14:00
Copyright for syndicated content belongs to the linked Source.
